menu search

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies Feedback obtained from U.S. Food and Drug Administration (FDA) Conference Call and Webcast on Monday, June 26, 2023, at 8:00 am Eastern Time THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) — Lexicon […] The post Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development appeared first on ForexTV... Read More
Posted: Jun 24 2023, 00:45
Author Name: forextv
Views: 111473

Search within

Pages Search Results: